Melanoma Response to Immunotherapy is regulated by B Cell-Derived Extracellular Vesicles
Ala’a Al HroutiD, Agshin Balayev, Karla Cervantes-GraciaiD, Konstantinos GkelisiD, Stephan Benke-BrudereriD, Julia M. Martínez GómeziD, Karīna SiliņaiD, Mitchell Paul LevesqueiD, Richard ChahwaniD
Abstract
The immune tumor microenvironment (TME) is increasingly recognized as a dynamic ecosystem where B cells play pivotal roles in modulating therapeutic responses, particularly in the context of immune checkpoint blockade (ICB) therapy. While B cells have traditionally been viewed as bystanders in tumor immunity, recent evidence suggests they may actively influence anti-tumor immunity, albeit with conflicting reports regarding their pro-tumor or anti-tumor roles. This study explores the crucial roles played by B cells and their secreted extracellular vesicles (EVs) in shaping melanoma responses to ICB therapy. We show a significant enrichment of B cells in ICB therapy responders compared to non-responders, pre-treatment, through retrospective analyses of melanoma patient tumors. Functional assays demonstrate that B cell depletion impairs T cell-mediated tumor cytotoxicity, underscoring the importance of B cells in anti-tumor responses. To investigate the clinical relevance, EVs were isolated from melanoma patient tumors, and fractioned into tumor and immune subpopulations. MiRNA profiling of CD19+ EVs identifies miR-99a-5p as a top candidate, among several others, upregulated in responders. Functional assays show that miR-99a-5p silencing in B cells diminishes T cell-mediated anti-tumor activity, suggesting its role in promoting B cell-mediated immune responses. Mechanistically, miR-99a-5p influences B cell maturation within the TME by mediating class-switch recombination. Our findings highlight the important role of B cells and their derived EVs in shaping the efficacy of melanoma immunotherapy, paving the way for novel therapeutic strategies targeting B cell-related pathways. Graphical abstract (created with Biorender) O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=177 SRC="FIGDIR/small/628150v1_ufig1.gif" ALT="Figure 1"> View larger version (60K): org.highwire.dtl.DTLVardef@144bbe6org.highwire.dtl.DTLVardef@18c1e9eorg.highwire.dtl.DTLVardef@2e37aaorg.highwire.dtl.DTLVardef@487e18_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 7
- FWCI
- 2.66
- Field percentile
- top 8%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
J. Griss, W. Bauer, … S. N. Wagner·bioRxiv·Jan 10, 2019
- NK cells contribute to resistance to anti-PD1 therapy in immune-excluded melanomas
E. Landeloos, J. Pozniak, … J.-C. Marine·bioRxiv·Dec 14, 2023
- Liver cells and PBMC secrete Tumor-suppressive Plasma Extracellular Vesicles in Melanoma patients
A. S. Baur, J.-H. Lee, … J. Vera-Gonzalez·bioRxiv·Oct 23, 2019
- Immune cell senescence drives responsiveness to immunotherapy in melanoma
Pavlos Pantelis, Dimitrios Christos Tremoulis, … Vassilis G. Gorgoulis·Molecular CancerPeer-reviewed·Dec 10, 2025
- Multiplexed Imaging Mass Cytometry of Chemokine Milieus in Metastatic Melanoma Characterizes Features of Response to Immunotherapy
T. Hoch, D. Schulz, … B. Bodenmiller·bioRxiv·Jul 29, 2021
- Tumor secreted extracellular vesicles regulate T-cell costimulation and can be manipulated to induce tumor-specific T-cell responses
X. Zhao, C. Yuan, … S. Subramanian·bioRxiv·Apr 22, 2020